Zotizalkib

Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM) . Zotizalkib has strong antitumor activities[1].

Product Specifications

CAS Number

[2648641-36-3]

Product Name Alternative

TPX-0131

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK)

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zotizalkib.html

Purity

98.02

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC([C@H]1N2C3=NC4=C(C(NC(C)(COC5=CC=C(F)C=C5C2)C)=O)C=NN4C=C3OC1)F

Molecular Formula

C21H20F3N5O3

Molecular Weight

447.41

References & Citations

[1]Brion W Murray, et al. TPX-0131, a Potent CNS-Penetrant, Next-Generation Inhibitor of Wild-Type ALK and ALK-Resistant Mutations. Mol Cancer Ther. 2021 Jun 22; molcanther.0221.2021.